Neurontin Settlement Of $430 Mil. Is High For Off-Label Case, Low For Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer's $430 mil. Neurontin off-label promotion settlement is the equivalent of about nine weeks of U.S. sales of the anti-epileptic brand